Local recurrence in primary localised resected gastrointestinal stromal tumours: A registry observational national cohort study including 912 patients

• Published in: European journal of cancer (1990) 2023-06, Vol.186, p.113-121
• Main Authors: Bleckman, Roos F., Roets, Evelyne, IJzerman, Nikki S., Mohammadi, Mohammed, Bonenkamp, Han J.J., Gelderblom, Hans, Mathijssen, Ron H.J., Steeghs, Neeltje, Reyners, Anna K.L., van Etten, Boudewijn
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - therapeutic use; Cohort Studies; Follow-up; Gastrointestinal Stromal Tumors - drug therapy; Gastrointestinal stromal tumour; Humans; Imatinib Mesylate - therapeutic use; Local recurrence; Neoplasm Recurrence, Local; Recurrence; Registries; Retrospective Studies; Treatment
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/j.ejca.2023.03.007

Previous literature showed a high risk of recurrence following surgical treatment in patients with gastrointestinal stromal tumours (GISTs). However, little is known about the patient- and treatment characteristics of local recurrences (LRs) in GIST patients. Therefore, this study aimed to better understand patterns of LR in surgically treated localised GIST and to describe treatment options based on our Dutch GIST Registry (DGR). Data of primary surgically treated localised GIST between January 2009 until July 2021 were retrospectively retrieved from the DGR. Of 1452 patients registered in the DGR, 912 patients were included in this study. Only 3.8% (35/912) of patients developed LR, including 20 patients with LR only and 15 patients with simultaneous LR and distant metastases (DM). Median time to LR was 30 (interquartile range 8–53) months from date of surgery. Eleven percent (100/912) of patients developed only DM. A total of 2.3% (6/259) of patients treated with adjuvant treatment developed an LR during adjuvant therapy. Seventy percent of patients with LR only (14/20) were treated with surgery (85.7% R0), which was mostly combined with systemic treatment. Patients with primary surgically treated localised GIST have a limited risk of developing recurrence. Fifteen percent developed recurrence, of which one quarter developed an LR. Therefore, less intensified follow-up schedules could be considered, especially during treatment with adjuvant imatinib. In patients with LR only, potentially curative treatment strategies, including surgical (re-)resection, are often possible as treatment for LR. •Primary surgically treated GISTs have only a limited risk of local recurrence (LR).•Patients who developed LR showed more aggressive and ruptured primary GIST.•In patients with LR only promising treatment strategies are still remaining.•Less intense follow-up could be considered during adjuvant treatment.•Less intense follow-up could also be considered after treatment with surgery only.